Biozentrum, University of Basel, Klingelbergstrasse 50/70, CH-4056 Basel, Switzerland.
Biochem Soc Trans. 2013 Aug;41(4):889-95. doi: 10.1042/BST20130113.
The atypical serine/threonine kinase mTOR (mammalian target of rapamycin) is a central regulator of cell growth and metabolism. mTOR is part of two multisubunit signalling complexes, mTORC1 and mTORC2. Although many aspects of mTOR signalling are understood, the lack of high-resolution structures impairs a detailed understanding of complex assembly, function and regulation. The structure of the kinase domain is of special interest for the development of mTOR inhibitors as anti-cancer agents. A homology model of the mTOR kinase domain was derived from the structure of PI3Ks (phosphoinositide 3-kinases). More recently, the crystal structure of the catalytic domain of human mTOR was determined, providing long-awaited structural insight into the architecture of mTOR. Interestingly, the homology model predicted several aspects of the crystal structure. In the present paper, we revisit the homology model in the context of the now available crystal structure of the mTOR kinase domain.
非典型丝氨酸/苏氨酸激酶 mTOR(雷帕霉素的哺乳动物靶标)是细胞生长和代谢的中央调节剂。mTOR 是两个多亚基信号复合物 mTORC1 和 mTORC2 的一部分。尽管已经了解了 mTOR 信号的许多方面,但缺乏高分辨率结构会妨碍对复合物组装、功能和调节的详细了解。激酶结构域的结构对于开发作为抗癌剂的 mTOR 抑制剂具有特殊意义。mTOR 激酶结构域的同源模型是从 PI3Ks(磷酸肌醇 3-激酶)的结构推导而来的。最近,人 mTOR 的催化结构域的晶体结构被确定,为 mTOR 的结构提供了期待已久的结构见解。有趣的是,同源模型预测了晶体结构的几个方面。在本文中,我们根据现在可用的 mTOR 激酶结构域的晶体结构重新审视了同源模型。